127 related articles for article (PubMed ID: 12555142)
21. The angiotensin-calcineurin-NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteinases-2/-9 in atrial myocytes.
Saygili E; Rana OR; Meyer C; Gemein C; Andrzejewski MG; Ludwig A; Weber C; Schotten U; Krüttgen A; Weis J; Schwinger RH; Mischke K; Rassaf T; Kelm M; Schauerte P
Basic Res Cardiol; 2009 Jul; 104(4):435-48. PubMed ID: 19148693
[TBL] [Abstract][Full Text] [Related]
22. [Structure and function of matrix metalloproteinases].
Olszyński K; Zimowska M
Postepy Biochem; 2009; 55(1):76-84. PubMed ID: 19514468
[TBL] [Abstract][Full Text] [Related]
23. Potential novel pharmacological therapies for myocardial remodelling.
Landmesser U; Wollert KC; Drexler H
Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
[TBL] [Abstract][Full Text] [Related]
24. Cardiac remodeling and failure: from molecules to man (Part III).
Fedak PW; Verma S; Weisel RD; Skrtic M; Li RK
Cardiovasc Pathol; 2005; 14(3):109-19. PubMed ID: 15914295
[TBL] [Abstract][Full Text] [Related]
25. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
Vanhoutte D; Schellings M; Pinto Y; Heymans S
Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
[TBL] [Abstract][Full Text] [Related]
26. Reversal mechanisms of left ventricular remodeling: lessons from left ventricular assist device experiments.
Margulies KB
J Card Fail; 2002 Dec; 8(6 Suppl):S500-5. PubMed ID: 12555165
[TBL] [Abstract][Full Text] [Related]
27. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling.
Manso AM; Elsherif L; Kang SM; Ross RS
Cardiovasc Res; 2006 Feb; 69(3):574-84. PubMed ID: 16253214
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinase proteomics: substrates, targets, and therapy.
Morrison CJ; Butler GS; Rodríguez D; Overall CM
Curr Opin Cell Biol; 2009 Oct; 21(5):645-53. PubMed ID: 19616423
[TBL] [Abstract][Full Text] [Related]
29. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes.
Wohlschlaeger J; Schmitz KJ; Schmid C; Schmid KW; Keul P; Takeda A; Weis S; Levkau B; Baba HA
Cardiovasc Res; 2005 Dec; 68(3):376-86. PubMed ID: 16024006
[TBL] [Abstract][Full Text] [Related]
30. Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model.
Foronjy RF; Sun J; Lemaitre V; D'Armiento JM
Hypertens Res; 2008 Apr; 31(4):725-35. PubMed ID: 18633185
[TBL] [Abstract][Full Text] [Related]
31. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling.
Dahl CP; Husberg C; Gullestad L; Waehre A; Damås JK; Vinge LE; Finsen AV; Ueland T; Florholmen G; Aakhus S; Halvorsen B; Aukrust P; Oie E; Yndestad A; Christensen G
Circ Heart Fail; 2009 Nov; 2(6):624-32. PubMed ID: 19919988
[TBL] [Abstract][Full Text] [Related]
32. Vascular remodeling and protease inhibition--bench to bedside.
Sluijter JP; de Kleijn DP; Pasterkamp G
Cardiovasc Res; 2006 Feb; 69(3):595-603. PubMed ID: 16387286
[TBL] [Abstract][Full Text] [Related]
33. Extracellular matrix remodeling in hypertensive heart disease.
Shirwany A; Weber KT
J Am Coll Cardiol; 2006 Jul; 48(1):97-8. PubMed ID: 16814654
[No Abstract] [Full Text] [Related]
34. Paracrine effects of cell transplantation: modifying ventricular remodeling in the failing heart.
Fedak PW
Semin Thorac Cardiovasc Surg; 2008; 20(2):87-93. PubMed ID: 18707639
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.
Lindsey ML; Iyer RP; Jung M; DeLeon-Pennell KY; Ma Y
J Mol Cell Cardiol; 2016 Feb; 91():134-40. PubMed ID: 26721597
[TBL] [Abstract][Full Text] [Related]
36. Biology of metalloproteinases.
Amălinei C; Căruntu ID; Bălan RA
Rom J Morphol Embryol; 2007; 48(4):323-34. PubMed ID: 18060181
[TBL] [Abstract][Full Text] [Related]
37. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis.
Heeneman S; Cleutjens JP; Faber BC; Creemers EE; van Suylen RJ; Lutgens E; Cleutjens KB; Daemen MJ
J Pathol; 2003 Jul; 200(4):516-25. PubMed ID: 12845619
[TBL] [Abstract][Full Text] [Related]
38. Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression.
Davis GE; Senger DR
Curr Opin Hematol; 2008 May; 15(3):197-203. PubMed ID: 18391785
[TBL] [Abstract][Full Text] [Related]
39. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine?
MacFadyen RJ
Curr Opin Pharmacol; 2007 Apr; 7(2):171-8. PubMed ID: 17317319
[TBL] [Abstract][Full Text] [Related]
40. MT1-MMP: a potent modifier of pericellular microenvironment.
Itoh Y; Seiki M
J Cell Physiol; 2006 Jan; 206(1):1-8. PubMed ID: 15920734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
